IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Agitation Alzheimer's Disease | Drug: AVP-923 (dextromethorphan/quinidine) Drug: Placebo | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease. |
- Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]Primary Endpoint: Agitation/Aggression Domain of NPI
- Safety and Tolerability [ Time Frame: 10 weeks ]Standard Measurements (e.g. AEs, ECG, Labs, PE and Neuro Exam)
- Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]Total NPI
- Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]Caregiver Distress for NPI Domains
- Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]NPI-4A (Composite of 4 NPI Domains)
- Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]NPI-4D (Composite of 4 NPI Domains)
- Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]Individual Domains of NPI
- ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Rating) [ Time Frame: 10 weeks ]Agitation and Overall
- PGIC Patient Global Impression of Change (PGI-C) [ Time Frame: 10 weeks ]Agitation (Rated by Caregiver)
- QoL-AD (Quality of Life - Alzheimer's Disease measure) [ Time Frame: 10 weeks ]
- ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory) [ Time Frame: 10 weeks ]
- CSI (Caregiver Strain Index) [ Time Frame: 10 weeks ]
- CSDD (Cornell Scale for Depression in Dementia) [ Time Frame: 10 weeks ]
- (MMSE) Mini-Mental State Examination [ Time Frame: 10 weeks ]
| Enrollment: | 220 |
| Study Start Date: | June 2012 |
| Study Completion Date: | September 2014 |
| Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: Placebo |
Drug: Placebo
Placebo capsules administered twice a day over a 10-week period
|
| Experimental: AVP-923 |
Drug: AVP-923 (dextromethorphan/quinidine)
AVP-923 capsules administered twice a day over a 10-week period
|
Detailed Description:
Eligible patients for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.
This is a multicenter, randomized, double-dummy, double-blind, placebo-controlled study, consisting of 10 weeks of treatment.
Up to 200 patients will be enrolled at approximately 30-40 centers in the US.
Study medication will be administered orally twice-daily from Day 1 through Day 70. Screening must occur within within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible patients will be randomized into the study.
Eligibility| Ages Eligible for Study: | 50 Years to 90 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Diagnosis of probable Alzheimer's disease (AD).
The patient has clinically significant symptoms of agitation secondary to AD, that interfere with daily routine and for which a prescription medication is deemed indicated, in the opinion of the investigator.
Either out-patients or residents of an assisted-living facility or a skilled nursing home.
CGI-S score is ≥ 4 (moderately ill) at screening and baseline.
Mini Mental State Examination (MMSE) score at screening between 8 and 28 (inclusive).
Caregiver who is able and willing to comply with all required study procedures, ensuring that the patient attends all study visits and takes the study medication as instructed. In order to qualify as a caregiver for this study, the individual should spend time with the patient for a minimum of 4 hours on 4 separate days per week.
Key Exclusion Criteria:
Patient has other type of dementia (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia).
Patients with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g. malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, certain cardiac conduction abnormalities including QTc prolongation, or unstable valvular heart disease).
Patients with myasthenia gravis.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01584440
Show 44 Study Locations
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Avanir Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01584440 History of Changes |
| Other Study ID Numbers: |
12-AVR-131 |
| Study First Received: | April 23, 2012 |
| Last Updated: | September 18, 2014 |
Additional relevant MeSH terms:
|
Alzheimer Disease Psychomotor Agitation Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Dyskinesias Neurologic Manifestations Psychomotor Disorders Neurobehavioral Manifestations Signs and Symptoms |
Dextromethorphan Quinidine Quinidine gluconate Antitussive Agents Respiratory System Agents Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Anti-Arrhythmia Agents Antimalarials |
ClinicalTrials.gov processed this record on June 22, 2017